Abstract: medRxiv preprint doi: https://doi.org/10.1101/2021.03.25.21254322; this version posted March 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 Impact of monoclonal antibody treatment on hospitalization and mortality among non- 2 hospitalized adults with SARS-CoV-2 infection 3 4 Authors: J. Ryan Bariola MD1, Erin K. McCreary PharmD1, Richard J. Wadas MD2, Kevin E. 5 Kip PhD3, Oscar C. Marroquin MD3, Tami Minnier MSN, RN4, Stephen Koscumb BS3, Kevin 6 Collins BS3, Mark Schmidhofer MD5, Judith A. Shovel BSN RN4, Mary Kay Wisniewski, MT 7 MA COM4, Colleen Sullivan MHA6, Donald M. Yealy MD2, David A Nace MD MPH7, David 8 T. Huang MD MPH2,8,9, Ghady Haidar MD1, Tina Khadem PharmD1, Kelsey Linstrum MS6,9, 9 Christopher W. Seymour MD MSc6,9, Stephanie K. Montgomery MS6,9, Derek C. Angus MD 10 MPH FRCP6,8,9, Graham M. Snyder MD SM1 11 1. Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of 12 13 14 Medicine, Pittsburgh, PA, USA 2. Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA 15 3. Clinical Analytics, University of Pittsburgh Medical Center, Pittsburgh, PA, USA 16 4. Wolff Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA 17 5. Division of Cardiology, Dept of Medicine, University of Pittsburgh School of Medicine, 18 Pittsburgh, PA, USA 19 6. UPMC Health System Office of Healthcare Innovation, Pittsburgh, PA, USA 20 7. Division of Geriatric Medicine, Department of Medicine, University of Pittsburgh, 21 22 23 Pittsburgh, PA, USA 8. Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.03.25.21254322; this version posted March 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 24 9. Clinical Research Investigation and Systems Modeling of Acute Illness (CRISMA) Center, 25 Department of Critical Care Medicine, University of Pittsburgh School of Medicine, 26 Pittsburgh, PA, USA 27 28 Corresponding Author: 29 Graham M. Snyder, MD SM 30 Address: 3601 Fifth Avenue, Suite 150, Pittsburgh, PA 15213 31 Phone/Fax: 412-647-6718/412-692-2768 32 Email: snydergm3@upmc.edu 33 Keywords: COVID-19, SARS-CoV-2, monoclonal antibodies, bamlanivimab, etesevimab, 34 casirivimab, imdevimab 35 2 medRxiv preprint doi: https://doi.org/10.1101/2021.03.25.21254322; this version posted March 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 36 ABSTRACT 37 Background: Monoclonal antibody (mAb) treatment may prevent complications of COVID-19. 38 We sought to quantify the impact of bamlanivimab monotherapy on hospitalizations and 39 mortality, as well as Emergency..